Published in Front Biosci (Landmark Ed) on June 01, 2011
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39
Inborn errors of human JAKs and STATs. Immunity (2012) 1.90
Tyk2 and Stat3 regulate brown adipose tissue differentiation and obesity. Cell Metab (2012) 0.97
Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol (2011) 0.93
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med (2015) 0.92
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT (2013) 0.91
TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One (2015) 0.88
TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One (2012) 0.84
A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol (2013) 0.83
SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget (2014) 0.83
TYK2 Promoter Variant and Diabetes Mellitus in the Japanese. EBioMedicine (2015) 0.82
Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis. J Immunol (2015) 0.82
Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology (2013) 0.81
Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol (2014) 0.79
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget (2015) 0.78
Deciphering host genotype-specific impacts on the metabolic fingerprint of Listeria monocytogenes by FTIR spectroscopy. PLoS One (2014) 0.78
Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). J Biol Chem (2015) 0.78
Eliminative signaling by Janus kinases: role in the downregulation of associated receptors. J Cell Biochem (2014) 0.76
Tyrosine kinase 2 promotes sepsis-associated lethality by facilitating production of interleukin-27. J Leukoc Biol (2014) 0.76
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncoimmunology (2015) 0.76
Regulation of Connexin43 Function and Expression by Tyrosine Kinase 2. J Biol Chem (2016) 0.75
Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Front Immunol (2017) 0.75
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
Production of type I IFN sensitizes macrophages to cell death induced by Listeria monocytogenes. J Immunol (2002) 2.54
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
STAT1 acts as a tumor promoter for leukemia development. Cancer Cell (2006) 2.00
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
[The Club of Female Professors of the Medical University Vienna]. Wien Med Wochenschr (2009) 1.60
A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood (2010) 1.50
Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol (2007) 1.44
The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J (2002) 1.38
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res (2004) 1.22
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood (2007) 1.18
PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One (2012) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol (2009) 1.05
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood (2010) 1.04
CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep (2013) 1.02
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood (2013) 1.02
The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J Leukoc Biol (2010) 1.01
The tumor suppressor function of STAT1 in breast cancer. JAKSTAT (2013) 1.00
Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection. PLoS Pathog (2012) 0.99
MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol (2013) 0.98
Macrophage and T cell produced IL-10 promotes viral chronicity. PLoS Pathog (2013) 0.98
Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology (2012) 0.97
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) (2009) 0.96
Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol (2005) 0.96
TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest (2004) 0.95
The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. Blood (2011) 0.94
The use of endogenous and exogenous reference RNAs for qualitative and quantitative detection of PRRSV in porcine semen. J Virol Methods (2005) 0.92
Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget (2011) 0.92
MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol Chem (2002) 0.92
Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther (2010) 0.91
The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol (2005) 0.91
c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. Blood (2011) 0.91
Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma. Biochimie (2012) 0.89
Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology (2012) 0.89
Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res (2008) 0.88
The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta (2013) 0.87
Inhibition of xenograft tumor growth and down-regulation of ErbB receptors by an antibody directed against Lewis Y antigen. J Pharmacol Exp Ther (2006) 0.87
Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood (2003) 0.87
Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology (2012) 0.87
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard. Oncotarget (2011) 0.85
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res (2009) 0.85
Analysis of the mitochondrial genome of cheetahs (Acinonyx jubatus) with neurodegenerative disease. Gene (2004) 0.84
Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Front Biosci (Landmark Ed) (2011) 0.84
Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies? Leuk Lymphoma (2008) 0.83
Type I interferons have opposing effects during the emergence and recovery phases of colitis. Eur J Immunol (2014) 0.82
ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. Neoplasia (2013) 0.81
Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". Biochem Biophys Res Commun (2007) 0.80
The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection. PLoS One (2013) 0.79
Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle (2013) 0.79
CDK6 and p16INK4A in lymphoid malignancies. Oncotarget (2013) 0.78
Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.76
A mouse model to identify cooperating signaling pathways in cancer. Nat Methods (2012) 0.76
Bcl-2: Live and let die. Oncoimmunology (2012) 0.76
Targeting PI3Kδ: One man's meat is another man's poison. Oncoimmunology (2013) 0.75
Variants in STAT5B associate with serum TC and LDL-C levels. J Clin Endocrinol Metab (2011) 0.75
Methods to study tumor surveillance using tumor cell transplantation into genetically engineered mice. Methods Mol Biol (2015) 0.75
Modeling BCR/ABL-driven malignancies in the mouse. Methods Mol Biol (2015) 0.75
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. Cancer Cell (2016) 0.75